Skip to Content


In the US, Encorafenib (encorafenib systemic) is a member of the drug class multikinase inhibitors and is used to treat Melanoma, Metastatic.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antineoplastic agent

Cytostatic agent

Chemical Name

Methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]}-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate (WHO)

Foreign Names

  • Encorafenibum (Latin)
  • Encorafenib (German)
  • Encoraf√©nib (French)
  • Encorafenib (Spanish)

Generic Names

  • Encorafenib (OS: USAN)
  • LGX 818 (ChemID) (IS)
  • NVP-LGX818-NXA (USAN) (IS)
  • UNII-8L7891MRB6 (USAN) (IS)

Brand Names

  • Braftovi
    Array BioPharma, United States; Pierre Fabre Dermatologie, Poland


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.